Ongoing Mereo BioPharma Group plc (MREO) Investigation: Protect Your Rights - Contact Levi & Korsinsky Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc ("Mereo BioPharma Group plc") (NASDAQ: MREO) concerning potential violations of the federal securities laws.
On December 29, 2025, before the market opened, Mereo announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). The company reported that neither study failed to achieve its primary efficacy endpoint of reduction in annualized clinical fracture rate compared to placebo.
Following this news, MREO's stock price fell over 89% to open at $0.25 per share.
If you suffered a loss on your Mereo BioPharma Group plc securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281594
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Investigation Underway: Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky Over Securities Law Violations
2026-01-26 12:32 AM EST
Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky
2026-01-26 12:30 AM EST
Ongoing Mereo BioPharma Group plc (MREO) Investigation: Protect Your Rights - Contact Levi & Korsinsky
2026-01-26 12:27 AM EST
Aug 22, 2025
" The EDGAR Next deadline is no longer a future concern—it is an immediate compliance requirement. Companies that fail to complete...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services